FAP-targeted PET/NIR in Lung Malignant Tumors
Recruiting · NCT07498933 · Observational (researchers observe without assigning treatment) · Lead sponsor: Peking University People's Hospital
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Single center, prospective, diagnostic study. Patients with stage II-IIIB resectable NSCLC diagnosed by pathology were included. After receiving standard neoadjuvant therapy (chemotherapy/immunotherapy/combination therapy), FAPI-PET/CT and fluorescence imaging were performed one week before surgery. During the surgery, a near-infrared fluorescence navigation system was used to locate the tumor lesion. After surgery, the tumor bed range was determined by pathological gold standards (HE staining+immunohistochemistry), and the predictive efficacy and localization accuracy of FAPI-PET/fluorescence were compared and analyzed.
Who can take part
Inclusion criteria
- Age between 18 and 70 years old;
- Have complete clinical and imaging data;
- Prior to neoadjuvant therapy, the biopsy pathology showed lung cancer;
- Able to retain sufficient tumor tissue for testing and research;
- Sign informed consent.
Exclusion criteria
- Previously combined with other malignant tumors or received other anti-tumor treatments;
- Failure to collect sufficient tumor tissue for testing and research;
- The duration of neoadjuvant therapy is less than 3 cycles;
- The dynamic scanning image quality of multimodal probe PET cannot meet the analysis standards or is missing;
- Lack of clinical and imaging data;
- There are situations where other researchers consider it inappropriate to participate in this study
Where it is running
1 location listed.
- Peking University People's Hospital - Beijing, Beijing Municipality, China